- Conditions
- Parkinson's Disease Psychosis
- Interventions
- Pimavanserin, Quetiapine
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 392
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Leiomyosarcoma
- Interventions
- LMP1/2 CTLs (ALCI - Group A), LMP1/2 CTLs (ALCI - Group B), LMP1/2 CTLs (ALCI - Group C), LMP2 CTLs (ALSCER - Group A), LMP2 CTLs (ALSCER - Group B), LMP2 CTLs (ALSCER - Group C), LMP1/2 CTLs (ALCI - Expansion - Group A), LMP1/2 CTLs (ALCI - Expansion Group B), LMP1/2 CTLs (ALCI - Expansion Group C)
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2020
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Denver, Colorado + 3 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel
- Biological · Drug
- Lead sponsor
- AskGene Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Autism Spectrum Disorder High-Functioning
- Interventions
- Assistive Soft Skills & Employment Training (ASSET)
- Behavioral
- Lead sponsor
- Florida Gulf Coast University
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Fort Myers, Florida
- Conditions
- Bacillus Anthracis (Anthrax)
- Interventions
- BioThrax®
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more
- Conditions
- Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
- Interventions
- Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin, Rituximab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Stanford, California • Denver, Colorado + 21 more
- Conditions
- Primary Open-angle Glaucoma (POAG), Ocular Hypertension
- Interventions
- SHP639 (n=60), Placebo Comparator (n=24)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Child Behavior Disorders
- Interventions
- Control - Provider Medication Alert Only, Intervention - Alert + CAP Review AND Enhanced BH Access
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 733 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Columbus, Ohio • Portland, Oregon + 1 more
- Conditions
- Lung Cancer, Adenocarcinoma
- Interventions
- Phase I - GM.CD40L.CCL21 Vaccinations, Phase II - GM.CD40L cells Vaccinations, Phase II - GM.CD40L.CCL21 Vaccinations
- Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Malignant Neoplasm, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia
- Interventions
- alvocidib, cytarabine, mitoxantrone hydrochloride, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Madison, Wisconsin
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Lumiliximab + FCR, FCR
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 9
- States / cities
- Gainesville, Florida • Miami, Florida • Chicago, Illinois + 5 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- glecaprevir (300mg)/pibrentasvir (120mg)
- Drug
- Lead sponsor
- Kirby Institute
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Ivaltinostat, Capecitabine
- Drug
- Lead sponsor
- CG Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Newport Beach, California • San Francisco, California + 13 more
- Conditions
- Sleep, Metabolism Changes, Circadian Rhythm, Lifestyle Factors, Sleep Hygiene, Sleep Hygiene, Inadequate, Sleep Deprivation, Insufficient Sleep, Circadian Misalignment, Circadian Dysregulation, Light Exposure
- Interventions
- Central Clock Misalignment, Peripheral Misalignment
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
- Biological
- Lead sponsor
- SillaJen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Irvine, California • Miami, Florida • St Louis, Missouri + 2 more
- Conditions
- Sleep
- Interventions
- Fibit + Coaching, Coaching, Fitbit
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Mantle Cell Lymphoma, Refractory Lymphoma
- Interventions
- Acalabrutinib, Venetoclax, Obinutuzumab
- Drug
- Lead sponsor
- Austin I Kim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
- Interventions
- CBX-12
- Drug
- Lead sponsor
- Cybrexa Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Austin, Texas • Houston, Texas + 1 more
- Conditions
- Hepatitis C, HepatoCellular Carcinoma
- Interventions
- Mailed outreach
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 53 Years to 74 Years
- Enrollment
- 12,386 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- Quavonlimab, Pembrolizumab, Pembrolizumab/Quavonlimab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Hackensack, New Jersey • Nashville, Tennessee + 2 more
- Conditions
- Pancreatic Cancer
- Interventions
- cetuximab, capecitabine, docetaxel, Erlotinib, Gemcitabine, Irinotecan, mitomycin C, rapamycin, conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Neoplasms, Breast
- Interventions
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more
- Conditions
- Depressive Symptoms, Depression
- Interventions
- Behavioral Activation Therapy app, Behavioral Activation Therapy app + EHR, Treatment as Usual
- Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 649 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina